Molecular Hydrogen as a Potential Clinically Applicable Radioprotective Agent

Ionizing radiation is widely used in diagnostic and therapeutic settings. However, it causes unavoidable biological damage. These effects are categorized as direct DNA damage and indirect damage via free radicals. Indirect damage is especially significant at low radiation doses. Hydroxyl radicals (•OH) are a major contributor to this indirect damage. Molecular hydrogen (H₂) has been proposed as a potential radioprotectant. It selectively scavenges •OH without affecting other signaling molecules. Prior research has shown H₂'s safety in animal and clinical studies. This gap motivated a review of H₂'s radioprotective mechanisms. No prior work had resolved H₂'s full range of protective effects. This paper aims to clarify its potential clinical use.

This review seeks to evaluate H₂ as a radioprotective agent. The specific problem is the lack of safe and effective radioprotectants in clinical practice. The motivation is to explore H₂'s mechanisms beyond antioxidant activity. The authors aim to synthesize findings on H₂'s radioprotective effects. They focus on both direct and indirect protective pathways. The study also investigates H₂'s role in inflammation and apoptosis. The goal is to assess H₂'s clinical viability. This paper does not propose new experiments but analyzes existing literature.

The authors conducted a literature review on H₂'s radioprotective effects. They analyzed animal studies and clinical trials for safety and efficacy. They examined H₂'s ability to scavenge •OH radicals. The review also considered H₂'s anti-inflammatory properties. Gene expression regulation by H₂ was another focus area. The authors compared H₂ to other radioprotectants in terms of safety. They evaluated H₂'s mechanisms at the cellular and molecular levels. The study does not involve new data collection but synthesizes published evidence.

H₂ selectively scavenges •OH radicals without affecting other reactive species. Animal studies show H₂ reduces radiation-induced tissue damage. Clinical trials report no significant adverse effects from H₂ use. H₂ modulates inflammatory responses and apoptosis pathways. It also influences gene expression related to DNA repair. H₂'s protective effects are observed at low concentrations. The mechanism involves both antioxidant and signaling pathways. These findings suggest H₂ is a promising radioprotective agent.

The authors conclude that H₂ has potential as a radioprotective agent. They emphasize H₂'s safety profile in animal and clinical studies. H₂'s mechanisms include scavenging •OH and modulating gene expression. The authors suggest H₂ may reduce radiation-induced inflammation. They note H₂'s role in anti-apoptotic pathways. The paper does not claim H₂ is essential but proposes it as viable. The authors highlight the need for further clinical validation. They do not suggest H₂ as a cure but as a protective supplement.